Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

Abstract Background Immune checkpoint inhibitors (ICIs) have been approved as second‐line therapy for advanced non–small cell lung cancers (NSCLCs) progressing after platinum‐based chemotherapy. However, some patients' disease progressed rapidly and sometimes exhibited explosive tumor progressi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Alain Vergnenegre, Margaux Geier, Florian Guisier, Regine Lamy, Bénédicte Comet, Gwenaelle Le Garff, Pascal Do, Henri Janicot, Hugues Morel, Chantal Decroisette, Michel Andre, Lionel Falchero, Nicolas Paleiron, Isabelle Monnet, the GFPC Team
Formato: Artigo
Lenguaje:Inglês
Publicado: Wiley 2020-01-01
Colección:Cancer Medicine
Materias:
immune checkpoint inhibitors
non–small cell lung cancer
rapid progression
second‐line treatment
Acceso en línea:https://doi.org/10.1002/cam4.2716
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares